Pune, India, Sept. 21, 2022 (GLOBE NEWSWIRE) -- According to MarketStudyReport, global biologics outsourcing market is projected to register a 12.5% CAGR during 2022-2028.
Furthermore, the document expands on the various segments such as product type, source, end-user ambit, application spectrum, regional terrain, and competitive landscape. The data is poised to ensure a considerable level of profitability for investors and other stakeholders looking to enter this business vertical.
Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/5517000/
The increasing adoption of advanced technologies for biological production, rising outsourcing of R&D activities by pharmaceutical & biopharmaceutical companies, and a favorable regulatory environment for clinical trials in developing countries are some of the chief factors propelling the overall market growth.
Furthermore, the increasing number of mergers & collaborations has boosted pharmaceutical & biopharmaceutical outsourcing, with major industry players expanding into developing regions.
Segmental Outline:
Based on product type, the market is segmented into antibodies, recombinant proteins, vaccines, and others. Out of these, the antibodies segment is estimated to witness a healthy CAGR during the analysis period. Moving on to the source, global biologics outsourcing market is bifurcated into human, microbial, and others. Among these, the microbial segment is expected to increase significantly. during the forecast period.
Ask Discount of this research report at @ https://www.marketstudyreport.com/check-for-discount/5517000/
As per the application spectrum, the industry is segmented into vaccine and therapeutics development, stem cell research, blood & blood-related product development, cellular and gene therapy product development, and others. The stem cell research segment is estimated to hold a prominent share in the market over the study period, owing to rising investments in this sector by multiple healthcare companies and governments. Based on end-user, the market covers the analysis of therapeutics & diagnostics, and research.
Regional Overview:
Credible researchers claim that Asia Pacific is projected to be a lucrative avenue for worldwide biologics outsourcing industry over the forecast period, attributed to the surging prevalence of non-communicable diseases, increasing demand for biologics, the growing pharmaceutical sector in the emerging economies, and rising government initiatives for the improvement of the health care arena.
Summarizing the Competitive Landscape:
Genscript Biotech Corp., Abbvie Inc., Rentschler Biopharma SE, Syngene International Ltd., ThermoFisher Scientific Inc., Samsung Biologics Co. Ltd., Catalent Inc., GL Biochem Corp., Abzena plc, Boehringer Ingelheim International GmbH, Wuxi Biologics (Cayman) Inc., and Lonza Group AG are the leading companies operating in the market.
To access a sample copy or view this report in detail along with the table of contents, please click the link below:
Global Biologics Outsourcing Market, By Product Type (Revenue, USD Million, 2019-2028)
- Vaccines
- Recombinant proteins
- Antibodies
- Antibody Drug Conjugates
- Monoclonal Antibody
- Others (Polyclonal Antibodies etc.)
- Others (Fusion Proteins, etc.)
Global Biologics Outsourcing Market, By Source (Revenue, USD Million, 2019-2028)
- Microbial
- Human
- Others (Transgenic Animals such as Avian, Insects, etc.)
Global Biologics Outsourcing Market, By Application Spectrum (Revenue, USD Million, 2019-2028)
- Cellular and Gene Therapy Products Development
- Blood & Blood-Related Products Development
- Vaccine and Therapeutics Development
- Stem Cell Research
- Others (Tissue & Tissue Related Products Development)
Global Biologics Outsourcing Market, By End-user Terrain (Revenue, USD Million, 2019-2028)
- Research
- Therapeutics and Diagnostics
Global Biologics Outsourcing Market, Regional Landscape (Revenue, USD Million, 2019-2028)
North America
- US
- Canada
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia Pacific
- Association of Southeast Asian Nations (ASEAN)
- Australia
- South Korea
- India
- China
- Japan
- Rest of Asia Pacific
Western Europe
- Nordic
- Benelux
- Italy
- Spain
- France
- UK
- Germany
- Rest of the Western Europe
Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
Middle East & Africa
- Turkey
- South Africa
- GCC
- Rest of MEA
Global Biologics Outsourcing Market, Competitive Sphere (Revenue, USD Million, 2019-2028)
- Genscript Biotech Corp.
- Abbvie Inc.
- Rentschler Biopharma SE
- Syngene International Ltd.
- ThermoFisher Scientific Inc.
- Samsung Biologics Co. Ltd.
- Catalent Inc.
- GL Biochem Corp.
- Abzena plc
- Boehringer Ingelheim International GmbH
- Wuxi Biologics (Cayman) Inc.
- Lonza Group AG
Table of Contents
1. Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
2. Assumptions and Acronyms
3. Executive Summary
3.1. Global Market in 2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
4. Research Methodology
5. Analysis of COVID-19 Impact and Road Ahead
6. Market Indicators and Background
6.1. Macro-Economic Factors
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, industry players' expenditures, and economic conditions among others
6.3. Supply Chain & Value Chain Analysis
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter's Five Forces Analysis
7. Rules & Regulations
8. Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
9. Global Biologics Outsourcing Market: Key Investment Analysis
9.1. By Leading Biologics Companies
9.2. Technological Assessment
9.3. By Region
9.4. M&A Activities
10. Global Biologics Outsourcing Market: Service Cost Analysis
10.1. By Service Type
10.1.1. Antibody Production Service
10.1.2. Custom Monoclonal Antibody Production Service
10.1.3. Custom Polyclonal Antibody Production Service
10.1.4. Protein Production Service
10.1.5. Gene Editing Service
Related Report:
Global Life Sciences BPO Market Size study, By Product Type (Pharmaceutical outsourcing, Medical devices outsourcing, Contract sales and marketing outsourcing, Others), and Regional Forecasts 2022-2028
Global Life Sciences BPO Market to reach USD XX million by 2028.Global Life Sciences BPO Market is valued at approximately USDXX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Life sciences business process outsourcing (BPO) is a delegation of one or more IT-intensive business processes to an external provider for managing and administrating the selected processes based on defined and measurable performance metrics. Life sciences BPO provides a wide range of services in R&D, drug registration, and product launch through a third-party provider. The growing trend of outsourcing employed by pharma and medical device companies, the growth of the pharmaceutical industry, coupled with the increasing number of clinical studies are the primary factors burgeoning the market growth across the globe.
About US:
Market Study Report is a hub for market intelligence products and services.
We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.
Our customers partner with Market Study Report, to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.
If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, is the platform that can help you in achieving any of these objectives.
